Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Six unapproved peptide injections popular in wellness circles could soon be sold by compounding pharmacies under a new draft policy from HHS — not the FDA. FDA scientists largely oppose the move, warning the peptides haven't been vetted for safety or effectiveness. Critics say well-tested drugs already exist for the conditions these peptides claim to treat, and that bypassing clinical trials could lead to real harm.
The U.S. Department of Health and Human Services (HHS), under Health Secretary Robert F. Kennedy Jr., has released a draft policy that would allow compounding pharmacies to sell six unapproved injectable peptides — bypassing the FDA's standard drug review process. FDA scientists, who had little input in drafting the policy, largely oppose it, warning the peptides haven't been adequately tested for safety or effectiveness in clinical trials.
The six peptides — BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500 — are promoted for conditions ranging from wound healing and obesity to migraines and insomnia. While pharmacies would be required to source ingredients from FDA-registered facilities and track side effects, former FDA official Dr. Peter Lurie notes the agency lacks legal authority to enforce those requirements. Much of the public promotion around peptides is also riddled with misleading claims — that they're "not drugs," that they're safe because they're "natural," and that Big Pharma suppresses them because they can't be patented (hundreds of peptide patents actually exist).
Key Takeaways:
Why it matters: Loosening access to unproven peptides without rigorous clinical trial data sets a troubling precedent — potentially diverting patients from effective, approved treatments toward substances with unknown risks, while also undermining the incentive for companies to invest in proper drug development.
